At 5.2% CAGR, the Asia Pacific Transdermal Medical Patch Market is projected to be worth US$ 2,744.32 million by 2028, says The Business Market Insights

According to the Business Market Insights’ research, the Asia Pacific transdermal medical patch market was valued at US$ 2,126.31 million in 2023 and is expected to reach US$ 2,744.32 million by 2028, registering a CAGR of 5.2% from 2023 to 2028. Increasing strategic initiatives and advancements in smart patches and three-dimensional (3D)-printed patches are the critical factors attributed to the Asia Pacific transdermal medical patch market expansion.                    

Products facilitating self-administration and home care drug delivery systems, as well as growing pharmaceutical company partnerships, are likely to accelerate the adoption of transdermal medical patches in the upcoming years. In February 2023, DuPont Healthcare collaborated with TNO Holst Centre and Pronat Medical to develop a new wearable medical adhesive concept patch for monitoring, diagnostics, or treatment. In December 2023, Henkel collaborated with Quad Industries to create a new concept enabling faster development of health patches for the medical industry.

Therefore, innovative technologies for medical patches are highly valued due to the enormous market growth potential and the need to improve the performance of these patches positively impact patient comfort and compliance. Such strategic initiatives will likely offer growth opportunities to market players and assist in attaining a significant position in the transdermal medical patch market.  

On the contrary, recalls of transdermal medical patches due to drug failure hurdles the growth of Asia Pacific transdermal medical patch market.

Based on type, the Asia Pacific transdermal medical patch market is segmented into single-layer drug in-adhesive, multi-layer drug in-adhesive, reservoir, vapor patch and matrix. The matrix segment held 34.9% market share in Asia Pacific transdermal medical patch market in 2023, amassing US$ 743.10 million. It is projected to garner US$ 989.41 million by 2028 to expand at 5.9% CAGR during 2023–2028.

Based on application, the Asia Pacific transdermal medical patch market is segmented into neurologic conditions, pain management, nicotine cessation, cardiovascular disorders, hormonal therapy, and others. The pain management segment held 32.8% market share in Asia Pacific transdermal medical patch market in 2023, amassing US$ 698.37 million. It is projected to garner US$ 916.07 million by 2028 to expand at 5.6% CAGR during 2023–2028.

Based on distribution channels, the Asia Pacific transdermal medical patch market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held 43.5% market share in Asia Pacific transdermal medical patch market in2023, amassing US$ 925.76 million. It is projected to garner US$ 1,163.59 million by 2028 to expand at 4.7% CAGR during 2023–2028

Based on country, the Asia Pacific transdermal medical patch market has been categorized into China, India, Japan, South Korea, Australia, and the Rest of Asia Pacific.  Our regional analysis states that Japan captured 30.5% market share in 2023. It was assessed at US$ 649.49 million in 2023 and is likely to hit US$ 858.68 million by 2028, exhibiting a CAGR of 5.7% during the forecast period.     

Key players dominating the Asia Pacific transdermal medical patch market are Boehringer Ingelheim International GmbH; Endo International Inc; Hisamitsu Pharmaceutical Co Inc; Johnsons and Johnsons; Medline Industries LP; Novartis AG; Teva Pharmaceutical Industries Ltd.; and Viatris Inc among others.   

• In Jan 2021, Notice regarding Obtaining Approval of Partial Change of Approved Matters of “Mohrus Paps XR 120 mg and 240 mg”, Transdermal Analgesic Anti-Inflammatory Patches
• In Jan 2020, Notification of approval for manufacturing and marketing approval of OABLOK PATCH in Thailand

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com